As of May 27
| +0.01 / +0.47%|
The 3 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 5.75, with a high estimate of 8.00 and a low estimate of 4.50. The median estimate represents a +168.69% increase from the last price of 2.14.
The current consensus among 3 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.